Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

NCT03945773 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib

Sponsor

Ipsen